TickerGuard
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

Butterfly Network Inc (BFLY)

Healthcare Medical Devices
7.10 $
-13.0% vs. previous close
Closing price · As of: 31. Jul 2026
🔔 Watch stock

Stock Watch

Stock Watch will tell you what changes at Butterfly Network Inc.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Trading Day

Previous Close
8.20$
Open
8.00$
Day High
8.00$
Day Low
7.10$
Volume
10,871,504shares

Key levels of the most recently completed trading day — not a live quote.

52-Week Range

52-Week Low 52-Week High
1.30 $ 8.90 $
08/08/2025 06/29/2026

Current price 7.10 $ — 76% of the range above the low.

Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.

Basics

Market Cap
1.8$B
Shares Outstanding
245Mio.
Float
83.0%
Beta
2.1

Performance

Perf. 1M
93.30%
Perf. 3M
127.30%
Perf. 6M
125.60%
YTD Performance (%)
101.80%
52-Week-High Distance
-10.3%
Perf. 1Y
315.79%
Perf. 3Y
176.65%
Perf. 5Y
-33.80%
Perf. Since Inception
-28.18%

Technical Indicators

MA 38 Days
7.10$
MA 50 Days
6.50$
MA 200 Days
4.40$
RSI (14)
50.3
Volatility 30 Days
170.8%
Volatility 250 Days
114.3%

Calculated from the price history · as of 08/03/2026

Valuation

P/E
Forward P/E
0.0
PEG
P/B
9.4
P/S
15.7
EV/EBITDA
-9.6
Price/FCF

Profitability

Gross Margin
68.2%
EBIT Margin
-50.8%
Net Margin
-66.8%
Return on Equity
-35.2%
Return on Assets
-10.5%

Balance Sheet & Safety

Equity Ratio
66.9%
Debt/Equity
0.1
warning zone
Altman Z″
-2.41
Piotroski
3 out of 9

Growth

Sales Growth Last Quarter
25.00%
EPS Growth Last Quarter
0.00%
Sales Growth (Year)
18.96%
Forward Sales Growth
19.66%
Forward EPS Growth
27.50%

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage
2
Top 10%
RS Rating
97
EPS Rating
42
Piotroski
3 out of 9
Fundamental Rating
B (57 out of 100)
warning zone
Altman Z″
-2.41

AI Rating

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built

Growth Score

5 of 10 Solid growth

Ten checks against the annual reports — each one passed counts a point.

  • Revenue grows by more than 15% a year over three years 10.0% failed
  • More than 10% revenue growth is expected for the coming year 19.7% passed
  • Share count grows by less than 3% a year 7.3% failed
  • Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 2.5% failed
  • Gross margin at 40% or higher and without meaningful erosion 46.9% passed
  • Goodwill from acquisitions does not grow faster than revenue 0.0% passed
  • Net debt below twice EBITDA 130 m net cash passed
  • Operating cash flow covers the profits of the last three years 130 m failed
  • Return on capital at 15% or higher, or up versus two years ago -37.3% failed
  • Insiders hold at least 10% or are net buyers 12.2% passed

A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Analysts & Price Target

Current Price 7.10 $
Price Target (average) 8.06 $

The price target sits 13.5% above the current price.

Consensus
Strong Sell
Analyst Ratings
4
Distribution of Recommendations
Strong Buy 4
Buy 0
Hold 0
Sell 0
Strong Sell 0

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Estimates by Fiscal Year

Estimates by Fiscal Year
Fiscal Year EPS Estimate ($) EPS Range ($) Revenue Estimate ($M) Expected Growth Analysts
12/31/2026 -0.09 -0.09 – -0.09 121 25.0% 1
12/31/2027 -0.07 -0.08 – -0.06 143 25.9% 3

Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.

Next Reporting Date

7. Aug 2026

Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)
2024: Q4 · 22.4 $M Q4 2025: Q1 · 21.2 $M Q1 2025: Q2 · 23.4 $M Q2 2025: Q3 · 21.5 $M Q3 2025: Q4 · 31.5 $M Q4 2026: Q1 · 26.5 $M Q1 2026: Q2 · 32.6 $M Q2

Source: fundamental data

Compare with other stocks →

Quarterly Figures

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q4 -0.09 22 35.30 -81.00 -3 -4
2025: Q1 -0.06 21 20.20 -65.80 -12 -12
2025: Q2 -0.06 23 8.80 -59.20 -7 -8
2025: Q3 -0.13 22 4.50 -158.10 -3 -4
2025: Q4 -0.06 32 41.00 -48.50 9 8
2026: Q1 -0.05 27 25.00 -47.80 -14 -15
2026: Q2 -0.05 16.70 33 39.30 -39.60 -16 -17
What Do These Terms Mean?
EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

Annual Figures

Annual Figures
Fiscal Year Revenue ($M) EBIT ($M) Net Income ($M) EPS ($) Operating Cash Flow ($M) Equity ($M) Total Assets ($M)
2018 2 -53 -51 -9.63 -70 242 248
2019 28 -102 -100 -16.45 -120 149 165
2020 46 -162 -163 -26.87 -82 -1 147
2021 63 -193 -32 -0.19 -189 448 572
2022 73 -193 -169 -0.84 -169 325 418
2023 66 -146 -134 -0.65 -99 220 304
2024 82 -74 -72 -0.34 -42 169 256
2025 98 -86 -77 -0.31 -13 196 297

Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.

About the Company

Butterfly Network, Inc. entwickelt, fertigt und vermarktet Ultraschall-Bildgebungslösungen in den USA und international.

Employees220
HeadquartersBurlington, MA
Address1600 District Avenue, 01803 Burlington, United States
Phone781 557 4800
Websitebutterflynetwork.com
IPO Date13. Jul 2020
ISINUS1241551027

Management

Management
Name Title Birth Year
Joseph M. DeVivo CEO, President & Chairman of the Board 1967
Jonathan M. Rothberg Ph.D. Founder & Director 1964
John N. Doherty Executive VP & CFO 1965
Steven Cashman Executive VP & Chief Business Officer 1977
Megan Carlson Chief Accounting Officer & Senior VP of Finance & Accounting 1984
Victor Ku Senior VP & CTO 1965
Kate Driscoll Vice President of Compliance, Quality & Regulatory
Nicholas Caezza VP & Deputy General Counsel & Corporate Secretary 1991
Mercedes Kelemen Vice President of Human Resources
John S. Soto Senior Vice President of International 1964

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
22. Jul 2026 Rothberg Jonathan M Director Sell 36,366 6.47 235,281
22. Jul 2026 Rothberg Jonathan M Director Sell 496,680 6.47 3,213,420
22. Jul 2026 Rothberg Jonathan M Director Sell 72,724 6.47 470,510
22. Jul 2026 Rothberg Jonathan M Director Sell 54,143 6.47 350,294
21. Jul 2026 Rothberg Jonathan M Director Sell 753,320 6.74 5,074,288
20. Jul 2026 Ku Victor Chief Technology Officer Sell 48,540 6.56 318,422
20. Jul 2026 Doherty John N. EVP, CFO Sell 57,136 6.56 374,812
20. Jul 2026 Devivo Joseph President & CEO Sell 211,798 6.56 1,389,395
20. Jul 2026 Rothberg Jonathan M Director Sell 1,177,276 6.61 7,786,268
17. Jul 2026 Rothberg Jonathan M Director Sell 1,195,857 6.60 7,887,753

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.

View all insider transactions →

Chart

Interactive price chart (TradingView).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?